Literature DB >> 1935494

Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor-alpha.

M Mahatma1, N Agrawal, E Z Dajani, S Nelson, C Nakamura, J Sitton.   

Abstract

Many of the complications of septic shock are believed to be a consequence of elevated circulating levels of tumor necrosis factor (TNF), which is an important mediator of tissue injury. Prostaglandins (PGs) of the E series have recently been reported to inhibit TNF production in vitro. We investigated the in vivo effect of misoprostol, a PGE1 analog, on endotoxin-induced gastric mucosal injury and TNF production. For the gastric mucosal injury studies, groups of animals were pretreated with intragastric misoprostol (100 and 200 micrograms/kg) or with antacid (2 ml/animal of Maalox Plus) 30 min prior to a challenge with intravenous E. coli lipopolysaccharide (LPS) at 5.0 mg/kg. Stomachs were examined 3 hr after LPS. Systemic endotoxin alone induced microscopic edema, vascular congestion, and polymorphonuclear (PMN) infiltration of the gastric mucosa. Pretreatment with misoprostol, but not with antacid, significantly and dose-dependently reduced the gastric mucosal injury. For the TNF studies, groups of rats were given either misoprostol (100 or 200 micrograms/kg, intragastric), or saline 1 hr prior to LPS challenge. Serum samples were obtained 1.5 hr after LPS challenge. Misoprostol dose-dependently and significantly (P less than 0.01) inhibited TNF activity. We conclude that misoprostol is a potent inhibitor of TNF systemic production and inhibits the gastric mucosal injury induced by endotoxemia. These studies suggest a potentially important therapeutic role for misoprostol in inflammatory diseases in which TNF exerts a contributory role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935494     DOI: 10.1007/bf01296398

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Platelet-activating factor or a platelet-activating factor antagonist decreases tumor necrosis factor-alpha in the plasma of mice treated with endotoxin.

Authors:  K M Ferguson-Chanowitz; A S Katocs; W C Pickett; J B Kaplan; P M Sass; A L Oronsky; S S Kerwar
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

Review 3.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

4.  Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury.

Authors:  A Robert; J E Nezamis; C Lancaster; A J Hanchar
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

5.  Gastric antiulcer and antisecretory effects of carbenoxolone, aldosterone and desoxycorticosterone in rats.

Authors:  E Z Dajani; R G Bianchi; J J Casler; J F Weet
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-11

6.  Morphology of rat gastric mucosal damage, defense, and restitution in the presence of luminal ethanol.

Authors:  S Ito; E R Lacy
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

7.  An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism.

Authors:  T H Pohlman; K A Stanness; P G Beatty; H D Ochs; J M Harlan
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

8.  TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.

Authors:  D Kwiatkowski; A V Hill; I Sambou; P Twumasi; J Castracane; K R Manogue; A Cerami; D R Brewster; B M Greenwood
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

Review 9.  Overview of the mucosal protective effects of misoprostol in man.

Authors:  E Z Dajani
Journal:  Prostaglandins       Date:  1987

10.  Differential regulation of tumor necrosis factor-alpha in human alveolar macrophages and peripheral blood monocytes: a cellular and molecular analysis.

Authors:  R M Strieter; D G Remick; J P Lynch; M Genord; C Raiford; R Spengler; S L Kunkel
Journal:  Am J Respir Cell Mol Biol       Date:  1989-07       Impact factor: 6.914

View more
  4 in total

1.  A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Authors:  Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

2.  Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta.

Authors:  T Watanabe; T Arakawa; T Fukuda; K Higuchi; K Kobayashi
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

3.  The degree of bacterial translocation is a determinant factor for mortality after burn injury and is improved by prostaglandin analogs.

Authors:  R Fukushima; L Gianotti; J W Alexander; T Pyles
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

4.  Misoprostol Inhibits Lipopolysaccharide-Induced Pro-inflammatory Cytokine Production by Equine Leukocytes.

Authors:  Emily Medlin Martin; Kristen M Messenger; Mary Katherine Sheats; Samuel L Jones
Journal:  Front Vet Sci       Date:  2017-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.